Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland
Cosmos Health (NASDAQ:COSM) has announced that its subsidiary, Decahedron , has successfully submitted a tender to supply NHS Scotland with C-Scrub Wash Chlorhexidine 4%, an antimicrobial wash. The tender is for 'Antiseptic Solutions and Hand Hygiene Products' and is invitation-only. C-Scrub offers immediate and prolonged antimicrobial action for up to 6 hours, targeting bacteria, viruses, and fungi without promoting resistance.
Cosmos Health plans to participate in additional tenders across the UK, including NHS England. The UK antibacterial products market is expected to grow from $656.5 million in 2020 to $733.0 million by 2028, with a CAGR of 1.4%. This move aligns with Cosmos Health's strategy to expand its presence in the UK healthcare market.
Cosmos Health (NASDAQ:COSM) ha annunciato che la sua controllata, Decahedron, ha presentato con successo un'offerta per fornire NHS Scotland con C-Scrub Wash Chlorhexidine 4%, un detergente antimicrobico. L'offerta è per 'Soluzioni Antiseptiche e Prodotti per l'Igiene delle Mani' ed è su invito. C-Scrub offre un'azione antimicrobica immediata e prolungata fino a 6 ore, mirata a batteri, virus e funghi senza favorire la resistenza.
Cosmos Health prevede di partecipare a ulteriori bandi nel Regno Unito, incluso NHS England. Si prevede che il mercato britannico dei prodotti antibatterici crescerà da 656,5 milioni di dollari nel 2020 a 733,0 milioni di dollari entro il 2028, con un CAGR dell'1,4%. Questa mossa è in linea con la strategia di Cosmos Health di espandere la sua presenza nel mercato sanitario del Regno Unito.
Cosmos Health (NASDAQ:COSM) ha anunciado que su filial, Decahedron, ha presentado con éxito una oferta para suministrar a NHS Scotland C-Scrub Wash Chlorhexidine 4%, un lavado antimicrobiano. La oferta es para 'Soluciones Antisépticas y Productos de Higiene de Manos' y es solo por invitación. C-Scrub ofrece acción antimicrobiana inmediata y prolongada durante hasta 6 horas, dirigida a bacterias, virus y hongos sin promover resistencia.
Cosmos Health planea participar en licitaciones adicionales en el Reino Unido, incluyendo NHS England. Se espera que el mercado de productos antibacterianos en el Reino Unido crezca de 656.5 millones de dólares en 2020 a 733.0 millones de dólares para 2028, con un CAGR del 1.4%. Este movimiento está alineado con la estrategia de Cosmos Health para expandir su presencia en el mercado de la salud del Reino Unido.
코스모스 헬스(Cosmos Health)(NASDAQ:COSM)는 자회사가 있는 Decahedron이 NHS 스코틀랜드에 C-Scrub Wash Chlorhexidine 4%를 공급하기 위한 입찰을 성공적으로 제출했다고 발표했습니다. 이 입찰은 '소독 솔루션 및 손위생 제품'에 관한 것이며 초대 전용입니다. C-Scrub는 최대 6시간 동안 즉각적이고 지속적인 항균 작용을 제공하며, 저항성을 촉진하지 않고 박테리아, 바이러스 및 곰팡이를 겨냥합니다.
코스모스 헬스는 영국 전역에서 추가 입찰에 참여할 계획입니다, NHS 잉글랜드를 포함해서요. 2020년 영국 항균 제품 시장은 6억 5,650만 달러에서 2028년까지 7억 3,300만 달러로 성장할 것으로 예상되며, 연평균 성장률(CAGR)은 1.4%입니다. 이 조치는 코스모스 헬스가 영국 의료 시장에서 입지를 확대하려는 전략과 일치합니다.
Cosmos Health (NASDAQ:COSM) a annoncé que sa filiale, Decahedron, a soumis avec succès une offre pour fournir NHS Scotland avec C-Scrub Wash Chlorhexidine 4%, un lavage antimicrobien. L'appel d'offres concerne 'Solutions Antiseptiques et Produits d'Hygiène des Mains' et est sur invitation seulement. C-Scrub offre une action antimicrobienne immédiate et prolongée pouvant aller jusqu'à 6 heures, ciblant les bactéries, les virus et les champignons sans favoriser la résistance.
Cosmos Health prévoit de participer à d'autres appels d'offres au Royaume-Uni, y compris NHS England. Le marché britannique des produits antibactériens devrait passer de 656,5 millions de dollars en 2020 à 733,0 millions de dollars d'ici 2028, avec un TCAC de 1,4%. Cette initiative est en accord avec la stratégie de Cosmos Health d'étendre sa présence sur le marché de la santé au Royaume-Uni.
Cosmos Health (NASDAQ:COSM) hat bekanntgegeben, dass ihre Tochtergesellschaft Decahedron erfolgreich ein Angebot zur Lieferung von NHS Scotland mit C-Scrub Wash Chlorhexidine 4%, einem antimikrobiellen Waschmittel, eingereicht hat. Das Angebot betrifft 'Antiseptische Lösungen und Produkte zur Handhygiene' und ist nur auf Einladung. C-Scrub bietet sofortige und langanhaltende antimikrobielle Wirkung für bis zu 6 Stunden und richtet sich gegen Bakterien, Viren und Pilze, ohne Resistenzen zu fördern.
Cosmos Health plant, an zusätzlichen Ausschreibungen im Vereinigten Königreich teilzunehmen, einschließlich NHS England. Der Markt für antibakterielle Produkte im Vereinigten Königreich wird voraussichtlich von 656,5 Millionen US-Dollar im Jahr 2020 auf 733,0 Millionen US-Dollar bis 2028 wachsen, mit einer durchschnittlichen jährlichen Wachstumsrate (CAGR) von 1,4%. Diese Maßnahme steht im Einklang mit der Strategie von Cosmos Health, ihre Präsenz im britischen Gesundheitsmarkt auszubauen.
- Successfully submitted tender to supply NHS Scotland with C-Scrub antimicrobial wash
- Invited to participate in NHS Scotland tender for 'Antiseptic Solutions and Hand Hygiene Products'
- Plans to participate in additional tenders across the UK, including NHS England
- UK antibacterial products market expected to grow to $733.0 million by 2028 (CAGR 1.4%)
- None.
Insights
The successful submission of Cosmos Health's tender for C-Scrub Wash Chlorhexidine 4% to NHS Scotland marks a significant step in the company's expansion strategy. This antimicrobial wash, with its 4% chlorhexidine gluconate formulation, offers several advantages in healthcare settings:
- Immediate and prolonged antimicrobial action for up to 6 hours
- Efficacy against bacteria, viruses and fungi without promoting resistance
- Suitability for iodine-sensitive users
- Inclusion of emollients for skin health
The product's potential applications across various healthcare environments, including hospitals, clinics and ICUs, position it well in the growing UK antibacterial products market. With the market expected to reach
However, it's important to note that while the tender submission is a positive step, it doesn't guarantee selection. The company will face competition from established players in the healthcare hygiene sector. Additionally, the projected
Cosmos Health's strategy to participate in additional tenders across the UK, including NHS England, demonstrates a commitment to market penetration. This approach could lead to economies of scale and strengthen the company's position in the healthcare products distribution sector. However, success will depend on factors such as pricing, supply chain efficiency and the ability to meet stringent NHS quality standards.
Cosmos Health's tender submission for C-Scrub to NHS Scotland represents a potential revenue stream, but its financial impact remains uncertain. Key considerations include:
- Market Opportunity: The UK antibacterial products market's projected growth to
$733.0 million by 2028 offers a substantial addressable market. - Revenue Potential: While specific contract values aren't disclosed, NHS supply agreements can provide stable, long-term income.
- Diversification: This move aligns with Cosmos Health's strategy as a vertically integrated healthcare group, potentially reducing reliance on other business segments.
- Competition: The invitation-only tender process suggests pre-qualification, but competition from established suppliers could affect margins.
- Scalability: Success with NHS Scotland could open doors to larger opportunities with NHS England, significantly expanding the revenue potential.
Investors should note that the
The company's ability to leverage this potential contract for improved financial performance will depend on factors such as production costs, distribution efficiency and the terms of any awarded contract. Additionally, the impact on the company's overall financial health should be considered in the context of its other business segments and overall growth strategy.
CHICAGO, IL / ACCESSWIRE / July 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Decahedron Ltd ("Decahedron"), has successfully submitted its tender to supply the National Health Service (NHS) in Scotland with its antimicrobial wash, C-Scrub Wash Chlorhexidine
Decahedron has been invited to participate in the NHS Scotland tender for "Antiseptic Solutions and Hand Hygiene Products." Participation in this tender process is conducted on an invitation-only basis. The Company has successfully submitted its tender to supply the NHS in Scotland with its C-Scrub antimicrobial wash in 250ml and 500ml pack sizes.
C-Scrub, with
Cosmos Health expects to participate in additional tenders across the United Kingdom, including those with NHS England.
According to Grand View Research, the antibacterial products market in the UK is expected to grow from
Suhel Bhutawala, Director of Decahedron, stated: "We are delighted to have been invited to participate in the tender for antiseptic solutions and hand hygiene products. Our team has successfully submitted our proposal, and we eagerly look forward to supplying NHS Scotland with our C-Scrub antimicrobial wash."
Greg Siokas, CEO of Cosmos Health, stated: "We are pleased to announce that we have successfully submitted our tender for C-Scrub and look forward to becoming a trusted supplier to NHS Scotland. The UK market is of great significance to Cosmos, and we are eager to participate in additional tenders for our products, including those for NHS England."
About the NHS
The National Health Service (NHS) is the publicly funded healthcare system in England and one of the four National Health Service systems in the United Kingdom. It is one of the world's largest single-payer healthcare systems. Funded primarily by the government through general taxation and supplemented by National Insurance contributions, the NHS is overseen by the Department of Health and Social Care. It provides healthcare services to all legal residents of England and residents from other UK regions, with most services being free at the point of use for most individuals. Additionally, the NHS conducts research through the National Institute for Health and Care Research (NIHR).
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What product has Cosmos Health (COSM) submitted for tender to NHS Scotland?
How long does the antimicrobial action of C-Scrub last?
What is the projected growth of the UK antibacterial products market by 2028?
Does Cosmos Health (COSM) plan to participate in other tenders in the UK?
